Analysts’ Ratings for Intercept Pharmaceuticals in April

Intercept Pharmaceuticals (ICPT) is a biopharmaceutical company focused on developing and commercializing novel therapeutics for the treatment of viral, progressive liver diseases utilizing its proprietary bile acid chemistry. Of the 20 analysts covering Intercept Pharmaceuticals in April 2018, ten of them have given the stock a “buy” or higher rating. Seven analysts have given it a “hold,” and three have given it a “sell.” The mean rating for the stock is 2.5 with a target price of $110.91.